Logo do repositório
 
Publicação

HER2 expression in circulating tumour cells isolated from metastatic breast cancer patients using a size-based microfluidic device

2021Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorLopes, Cláudia
dc.contributor.authorPiairo, Paulina
dc.contributor.authorChícharo, Alexandre
dc.contributor.authorAbalde-Cela, Sara
dc.contributor.authorPires, Liliana R.
dc.contributor.authorCorredeira, Patrícia
dc.contributor.authorAlves, Patrícia
dc.contributor.authorMuinelo-Romay, Laura
dc.contributor.authorCosta, Luis
dc.contributor.authorDiéguez, Lorena
dc.date.accessioned2021-09-20T14:54:43Z
dc.date.available2021-09-20T14:54:43Z
dc.date.issued2021
dc.description© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).pt_PT
dc.description.abstractHER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot of the tumour burden. Liquid biopsy offers the unique opportunity for low invasive sampling in cancer patients and holds the potential to provide valuable information for the clinical management of cancer patients. This study assesses the performance of the RUBYchip™, a microfluidic system for CTC capture based on cell size and deformability, and compares it with the only FDA-approved technology for CTC enumeration, CellSearch®. After optimising device performance, 30 whole blood samples from metastatic breast cancer patients were processed with both technologies. The expression of HER2 was assessed in isolated CTCs and compared to tissue biopsy. Results show that the RUBYchipTM was able to isolate CTCs with higher efficiency than CellSearch®, up to 10 times more, averaging all samples. An accurate evaluation of different CTC subpopulations, including HER2+ CTCs, was provided. Liquid biopsy through the use of the RUBYchipTM in the clinic can overcome the limitations of histological testing and evaluate HER2 status in patients in real-time, helping to tailor treatment during disease evolution.pt_PT
dc.description.sponsorshipThis work was supported by the CANCER project (NORTE-01-0145-FEDER-000029) co-funded through the NORTE-45-2015-02 program, the RESOLVE project (NORTE-01-0246-FEDER-000018) funded through the Norte2020, and the Safe-N-Medtech project (H2020-NMBP-02-2018) funded through Horizon 2020. The project leading to these results has also received funding and support from the “la Caixa” Foundation under CaixaImpulse Grant LCF/TR/CC20/52480003 (CTC-OD).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCancers (Basel). 2021 Sep 3;13(17):4446pt_PT
dc.identifier.doi10.3390/cancers13174446pt_PT
dc.identifier.eissn2072-6694
dc.identifier.urihttp://hdl.handle.net/10451/49548
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationNORTE-01-0145-FEDER-000029pt_PT
dc.relationNORTE-45-2015-02pt_PT
dc.relationNORTE-01-0246-FEDER-000018pt_PT
dc.relationH2020-NMBP-02-2018pt_PT
dc.relation.publisherversionhttps://www.mdpi.com/journal/cancerspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectHER2pt_PT
dc.subjectBreast cancerpt_PT
dc.subjectCirculating tumour cellspt_PT
dc.subjectLiquid biopsypt_PT
dc.subjectMicrofluidicspt_PT
dc.subjectOverall survivalpt_PT
dc.titleHER2 expression in circulating tumour cells isolated from metastatic breast cancer patients using a size-based microfluidic devicept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue17pt_PT
oaire.citation.titleCancerspt_PT
oaire.citation.volume13pt_PT
person.familyNameMartins Corredeira
person.familyNameBorges Alves
person.familyNameCosta
person.givenNamePatrícia Isabel
person.givenNamePatrícia
person.givenNameLuis
person.identifier.ciencia-id5F17-80B5-8509
person.identifier.ciencia-id0310-2648-AA9F
person.identifier.ciencia-id041E-4ADE-FB64
person.identifier.orcid0000-0001-7075-3516
person.identifier.orcid0000-0002-0650-2445
person.identifier.orcid0000-0002-4782-7318
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationed359223-803e-4417-80ad-2aaa03f4596c
relation.isAuthorOfPublicationed9d3206-25ad-47a1-98e5-c6548bc1bbec
relation.isAuthorOfPublication8a2ab4c6-ba86-4433-b4b7-6256d81890e5
relation.isAuthorOfPublication.latestForDiscovery8a2ab4c6-ba86-4433-b4b7-6256d81890e5

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
HER2.pdf
Tamanho:
4.18 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais